Osteopore and SingHealth partnership announcement

Osteopore Limited (ASX: $OSX) has announced its partnership with SingHealth to establish Osteopore's first Global Centre of Excellence (GCoE) for customised medical devices. The GCoE, located at the SGH Campus, will enable Osteopore to co-develop, test, validate, adopt, and scale its customised medical device globally, while deepening collaboration with SGH's clinicians and accelerating adoption. The partnership agreement, signed by Osteopore's wholly owned Singaporean subsidiary, Osteopore International Pte Ltd, is expected to conclude in H2 2026.

Executive commentary on the partnership

I'm delighted to solidify Osteopore's partnership with SingHealth and to cement our presence on the SGH Campus to support the global expansion plans of our customised medical device. With SGH-based clinicians on our Advisory Panel, we look forward to their contributions to our GCoE. SGH was ranked the number one Academic Medical Centre (AMC) in East Asia - and placed 8th globally - by Brand Finance in the Global Top 250 Hospitals 2023 Report. This partnership breaks new ground for Osteopore, enabling us to harness our customised medical device to improve patient outcomes to enhance patients' quality of life. We are looking forward to creating synergies that not only enhance the impact on health but also help to scale our customised medical device within the region around the globe.

Summary of Osteopore and SingHealth partnership

Osteopore's partnership with SingHealth to establish the Global Centre of Excellence (GCoE) for customised medical devices at the SGH Campus marks a significant milestone for the company. The GCoE will provide Osteopore with a dedicated workspace to co-develop, test, validate, adopt, and scale its customised medical device globally, while benefiting from financial support via the Enterprise Development Grant (EDG) from Enterprise Singapore. The partnership agreement includes a total partnership fee of S$284,485, payable by OSX monthly over 30 months, with up to 70% of qualified costs supported by Enterprise Singapore. Additionally, the appointment of three SGH clinicians to Osteopore's Advisory Panel will guide the development and testing of the customised medical device framework, using SGH as a clinical reference site. Osteopore aims to demonstrate its capability to offer high-value products that result in high-value care, ultimately improving patient quality of life and reducing overall healthcare costs. The company's ambitions to harness its customised medical device to improve patient outcomes and enhance patients' quality of life align with the growing global custom medical device market, which is expected to grow at a CAGR of 6.3% from 2023-2029.